From: A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Parameter | LY2603618/gemcitabine | Gemcitabine |
---|---|---|
(n = 65) | (n = 34) | |
Age, years | ||
 Mean (SD) | 64.3 (8.3) | 64.4 (10.1) |
 Median | 64.0 | 65.5 |
 Range | 47–83 | 39–90 |
Gender, n (%) | ||
 Female | 23 (35.4) | 14 (41.2) |
 Male | 42 (64.6) | 20 (58.8) |
Race, n (%) | Â | Â |
 White | 62 (95.4) | 32 (94.1) |
 Black or African American | 2 (3.1) | 2 (5.9) |
 American Indian or Alaska Native | 1 (1.5) | 0 |
BSA at baseline (m2) | ||
 Mean (SD) | 1.8 (0.2) | 1.8 (0.2) |
 Median | 1.8 | 1.7 |
 Range | 1.3–2.5 | 1.4–2.5 |
Disease stage, n (%) | ||
 II | 6 (9.2) | 3 (8.8) |
 III | 8 (12.3) | 5 (14.7) |
 IV | 50 (76.9) | 26 (76.5) |
 Unknown | 1 (1.5) | 0 |
ECOG PS, n (%) | ||
 0 | 28 (43.1) | 14 (41.2) |
 1 | 31 (47.7) | 17 (50) |
 2 | 6 (9.2) | 3 (8.8) |